Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Blanchet

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Plos One|August 23, 2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPascaline Boudou-Rouquette, Céline Narjoz, Jean Louis Golmard, et al.
Blood|September 28, 2002
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitorsStéphane Giraudier, Hédia Chagraoui, Emiko Komura, et al.
Aging Cell|December 13, 2022
High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBPLéa Montégut, Adrien Joseph, Hui Chen, et al.
Clinical Biochemistry|January 7, 2015
Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cellsFlorian Lemaitre, Benoit Blanchet, Marianne Latournerie, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2017
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in FranceClément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Pharmaceutics|July 27, 2022
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast CancerPerrine Courlet, Evelina Cardoso, Carole Bandiera, et al.
British Journal of Cancer|March 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patientsAlicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Plos One|August 23, 2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPascaline Boudou-Rouquette, Céline Narjoz, Jean Louis Golmard, et al.
Blood|September 28, 2002
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitorsStéphane Giraudier, Hédia Chagraoui, Emiko Komura, et al.
Aging Cell|December 13, 2022
High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBPLéa Montégut, Adrien Joseph, Hui Chen, et al.
Clinical Biochemistry|January 7, 2015
Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cellsFlorian Lemaitre, Benoit Blanchet, Marianne Latournerie, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2017
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in FranceClément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Pharmaceutics|July 27, 2022
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast CancerPerrine Courlet, Evelina Cardoso, Carole Bandiera, et al.
British Journal of Cancer|March 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patientsAlicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, et al.
Pageof 11